Grand Pharma Announces Successful Phase II Results for Innovative Sepsis Treatment STC3141
Grand Pharmaceutical Group Ltd has announced successful Phase II clinical study results for its innovative sepsis treatment, STC3141, which demonstrated significant efficacy in rebuilding immune homeostasis.
- Grand Pharmaceutical Group Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read